Brief: Bellerophon Announces Top-Line Data From Phase 3 Rebuild Clinical Trial Of INOpulse
05/06/2023 12:55
June 5 (Reuters) - Bellerophon Therapeutics Inc
BLPH.O :
* BELLEROPHON ANNOUNCES TOP-LINE DATA FROM PHASE 3 REBUILD
CLINICAL TRIAL OF INOPULSE® FOR TREATMENT OF FIBROTIC
INTERSTITIAL LUNG DISEASE
* BELLEROPHON THERAPEUTICS INC - TRIAL DID NOT MEET ITS
PRIMARY
ENDPOINT RELATED TO CHANGE IN MODERATE TO VIGOROUS PHYSICAL
ACTIVITY
* BELLEROPHON THERAPEUTICS - OVERALL, INOPULSE
WELL-TOLERATED WITH
NO SAFETY CONCERNS, CONSISTENT WITH WHAT HAS BEEN OBSERVED IN
PRIOR PHASE 2 STUDIES
* BELLEROPHON THERAPEUTICS INC - SECONDARY ENDPOINTS
DEMONSTRATED
MINIMAL DIFFERENCE BETWEEN TWO GROUPS WITH NONE APPROACHING
STATISTICAL SIGNIFICANCE
Source text for Eikon: ID:nGNX6cPq36
Further company coverage: BLPH.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Bellerophon Therapeutics
See all newsBrief: Bellerophon Therapeutics Inc On October 12, 2023, Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Nucor, Copper miners
U.S. STOCKS ON THE MOVE-Hubbell, Spire Global, FibroGen